We identified patients with diabetes and CKD stage 5 not on dialysis who received erythropoietin (erythropoietin‐stimulating agent), a drug reimbursed for patients with an estimated glomerular filtration rate <15 mL/min/1.73 m2. Here, EPO is linked to diabetes mellitus.